8th November 2018
Drug Discovery News
Sygnature Discovery in multi-target drug discovery deal with Sitryx Therapeutics
15th August 2018
DMPK Drug Discovery News
Sygnature Discovery Announces Expansion at Alderley Park
10th May 2018
Blog DMPK Therapeutic Areas
Understanding & Predicting Brain Penetration for CNS-targeted Drugs
2nd May 2017
Drug Discovery
Sygnature Discovery Expands Biophysics Capability with the Introduction of Biacore 8K SPR System
29th March 2017
Drug Discovery
TopiVert and Sygnature Discovery: A Dual Triumph as Two Drug Candidates Commence Clinical Trials
1st February 2017
Drug Discovery Therapeutic Areas
Sygnature Discovery, Mironid®, and Peak Proteins Join Forces to Tackle Incurable Kidney Disease, ADPKD
13th October 2016
Drug Discovery
Sygnature is exhibiting at ELRIG’s Drug Discovery 2016 event at the ACC, Liverpool. Stand G1
5th October 2016
Drug Discovery Therapeutic Areas
Sygnature Discovery and Viramatix Forge Strategic Alliance for Advancing Anti-Viral Drug Discovery
20th July 2016
Drug Discovery
Sygnature Discovery’s drug discovery capabilities enhanced by acquisition of BMG LABTECH PHERAstar® FSX
4th July 2016
Drug Discovery
Integration of the ImageXpress® Micro Confocal High-Content Imaging System
16th March 2016
Drug Discovery
The Adoption of IncuCyte® ZOOM enhances Sygnature Discovery’s Capabilities
30th July 2015
Drug Discovery
Sygnature Discovery Successfully Provides Clinical Candidate to Corcept Therapeutics